Address: 391 Technology Way, Winston-Salem, NC 27101
Email: [email protected]

Core Management Team

CEO and Co-founder 15+ years of global CEO experience (dual citizen: US, FIN) Tom Alapaattikoski
*Building high multiple exits M.Sc. (Tech), MBA.
*Raising global investments  “Serial tech entrepreneur.”
*Hiring high-performance teams

Head of Products Dr. Eva Mueller, Ph.D. “Tissue engineering superstar.” 

Head of Science  Dr. Matthew Brovold,  Ph.D. “Science operations grand master.” 

Head of AM Tech Tomi Kalpio, M.Eng. Co-Founder. “3D bioprinting mastermind.” 


Extensive advisory board + substantial clinical support

“There is a benefit to 3D printed implants over autologous tissue.” 

Adam Katz, M.D., reconstructive surgeon; Wake Forest Medical School, North Carolina, USA 

“There is a potential huge market and need for this.”  

John Hubbard, M.D., orthopedic surgeon; Atrium WF Baptist, North Carolina, USA

Nose-BioMod 510(k) roadmap funding needs exit strategy
  • Small animal studies 2024.
  • Safety profile studies 2025.
  • Commercial 2026. 
  • $2.25M-budget to commercialize Nose BioMod™ in 2026. 
  • Early exit/strategic acquisition very possible (Stryker, J&J, Arthrex etc.).
Business Description
Brinter’s 3D bioprinted Human BioMods™ platform offers improved regenerative medicine capabilities for nasal surgeries (primary) and orthopedic repairs. In the US alone, over 350k rhinoplasties are performed every year. The nose is highly vascularized and prone to inflammation with incompatible materials. Moreover, additional cartilage tissue is often needed during the various nasal procedures, leading to painful harvesting surgeries. With our novel Nose-BioMod™, we are offering a unique combination of universal cartilage material and 3D printing technology – reducing the morbidity associated with ear/rips harvest, expensive donor site, and using artificial materials. After Nose-BioMod™, we are broadening products to other cartilaginous regions of the body, i.e., meniscus, joints, intervertebral disc, and future tissue models – bone. The development of our cartilage BioMods™ is currently pre-clinical at Wake Forest Institute for Regenerative Medicine in North Carolina.
  • The current standard of care for cartilage replacement has high costs and pain associated with ear/ribs harvest, donor site, and high morbidity issues with synthetic extension grafts, prone to inflammation and rejection.
  • Nose-BioMod™: Cosmetic reconstructive procedures, dorsal augmentation rhinoplasty, and deviated septum surgeries are rising everywhere.
  • Implantable 3D Bioprinted BioMods™ with regenerative medicine capabilities and 100% resorbable biosynthetic composition.
  • Durable and functional design; easily integrated into existing surgical procedures.
  • Profitable unit economics for the payee and the payer with reimbursement opportunities and low-cost patented in-house 3D bioprinting technology.
Target market competitors competitive advantage
  • Nose-Biomod™: $1B+  rhinoplasty market in US (8%).
  • $10B+ cartilage replacements. 
  • Harvest surgery, Stryker
  • Medpor, polydioxanone plate.
  • NanoChon,
  • Affordable cartilaginous material  with improved tissue regeneration  through biosynthetic composition.